Clinical Trials Logo

Clinical Trial Summary

This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study. Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea. This study is seeking patients who: - Are 2 to less than 18 years of age; - Are given Xeljanz for the treatment of JIA. The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05754710
Study type Observational
Source Pfizer
Contact
Status Active, not recruiting
Phase
Start date April 12, 2024
Completion date January 24, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05411211 - An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Completed NCT02141984 - Surveillance of Humira in Korean JIA Patients N/A
Completed NCT04018599 - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS Phase 1
Completed NCT00144625 - Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Phase 3